Novartis AG

Type: Company
Name: Novartis AG
Nationality: Switzerland
Web Address: http://www.novartis.com
Fact Sheet: Fact Sheet for Novartis India Ltd
First reported 5 hours ago - Updated 23 mins ago - 4 reports

Novartis sees Alcon as $35M Fort Worth data center

FORT WORTH - A $35 million global data center will be built at Alcon’s campus by its owner and Swiss pharmaceutical giant, Novartis.The data center will serve operations in North America and South America for Novartis.The 10,000-sf data center will be ... [Published Real Estate Center - 23 mins ago]
First reported 20 hours ago - Updated 26 mins ago - 13 reports

Novartis' Enbrel beater nears a soon-to-crowd psoriasis market

Novartis' ($NVS) in-development drug secukinumab beat out the blockbuster Enbrel in improving symptoms of psoriasis in Phase III, improving the company's odds of success in what promises to be a competitive race among next-generation therapies for the ... [Published FierceBiotech - 26 mins ago]
First reported 4 hours ago - Updated 3 hours ago - 6 reports

Microbix sues Novartis in Europe over Virusmax patent

Mr. Vaughn Embro-Pantalony reportsMICROBIX SUES NOVARTIS FOR INFRINGEMENT OF ITS VIRUSMAX PATENT IN EUROPEMicrobix Biosystems Inc. has commenced a new patent litigation in the Court of Dusseldorf, Germany, against Novartis Vaccines and Diagnostics, alleging ... [Published Stockwatch - 3 hours ago]
First reported 20 hours ago - Updated 20 hours ago - 1 reports

NOVARTIS : An Application for the Trademark "HABITROL TAKE CONTROL SUPPORT PROGRAM" Has Been Filed by Novartis

By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C. , by NewsRx journalists, a trademark application has been made for "HABITROL TAKE CONTROL SUPPORT PROGRAM" by Mary F. Leheny , representing ... [Published 4 Traders - 20 hours ago]
First reported Jul 08 2014 - Updated 21 hours ago - 2 reports

Novartis Personalized Cell Therapy Receives FDA Breakthrough Therapy Designation

Novartis reported that FDA granted breakthrough therapy status to CTL019, an investigational chimeric antigen receptor (CAR) therapy for the treatment of pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL). The ... [Published PharmTech.com - 21 hours ago]
First reported Jul 09 2014 - Updated Jul 09 2014 - 5 reports

Novartis (VTC:NOVZn) publishes 2013 Corporate Responsibility Performance Report

The report enhances the company's transparency in several key areas, including in human resources, supply chain and ethics, and aims to meet the needs and expectations of CR professionals by offering easy access to key data ... [Published CorporateRegister.com - Jul 09 2014]
First reported Jul 08 2014 - Updated Jul 09 2014 - 2 reports

Sandoz Launches Generic Diovan in the U.S.

Sandoz announced the U.S. introduction of an authorized generic version of Diovan (valsartan) tablets for the treatment of high blood pressure (HBP).This launch follows the Sandoz U.S. introduction of an authorized generic version of Diovan HCT (valsartan ... [Published Drug Discovery and Development - Jul 09 2014]
First reported Jul 09 2014 - Updated Jul 09 2014 - 2 reports

Novartis, UGBS Empower Businesses

By Masahudu Ankiilu Kunateh,Email: [email protected]The Centre for Sustainability and Enterprise Development (CSED) at the University of Ghana Business School (UGBS) has organized a Business Skills Training Programme in conjunction with Novartis; the ... [Published Ghanaian Chronicle - Jul 09 2014]
First reported Jul 09 2014 - Updated Jul 09 2014 - 1 reports

New guidelines for IITs

Novartis has released new global guidelines for Investigator Initiated Trials (IITs). The company has a strong history of supporting the funding of IITs governed by internal operating processes and governance measures.Novartis defines IITs as studies ... [Published Pharma Field - Jul 09 2014]
First reported Jul 08 2014 - Updated Jul 08 2014 - 5 reports

Incyte Get $25M Milestone Payment from Novartis after Jakavi® Approval in Japan

Incyte Corporation announced today that it has earned a $25 million milestone payment from Novartis in connection with the approval of Jakavi® (ruxolitinib) in Japan for the treatment of patients with myelofibrosis. Incyte will record this amount as contract ... [Published PharmaceuticalProcessing - Jul 08 2014]
First reported Jul 08 2014 - Updated Jul 08 2014 - 2 reports

Novartis' CTL109 Gets Breakthrough Therapy Designation from…

Novartis ( NVS - Snapshot Report ) announced that the FDA has granted Breakthrough Therapy Designation to its pipeline candidate, CTL019.Novartis is evaluating CTL019, an experimental chimeric antigen receptor (CAR) therapy, for the treatment of pediatric ... [Published Zacks.com - Jul 08 2014]
First reported Jul 08 2014 - Updated Jul 08 2014 - 2 reports

Novartis unveils new guidelines for investigator-initiated trials

:15 in Pharmaceutical Company Restructures Novartis has announced the publication of new global guidelines for investigator-initiated trials (IITs) as part of its commitment to supporting ethical clinical research. IITs are studies developed and sponsored ... [Published Zenopa - Jul 08 2014]

Quotes

"He will be a valuable member of our executive leadership team and a guiding force for effectively executing the development strategy for our organization" he said in a statement
"Digital work continues to level the playing field, providing a common and cost-effective platform for brands to connect with their audiences."
Vaughn Embro-Pantalony, president and chief executive officer, said: "Microbix discovered the presence of large quantities of flu virus in eggs that was previously unrecognized by the industry. Virusmax is the innovative manufacturing process developed by Microbix for the vaccine industry based onon that discovery. Following the successful defense of our European patent in January, 2014, we are taking this next step to enforce our intellectual property rights in Europe."
...any statements preceded by, followed by or that include the words "targets", "believes", "expects", "aims", "intends", "will may", "anticipates", "would, "could" or similar expressions or negatives thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company's control that could cause the actual results, performance or achievements of the Group to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Group's present and future business strategies and the environment in which the Group will operate in the future. These forward-looking statements speak only as at the date of this document. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based unless required to do so by applicable law or the AIM Rules for Companies."

More Content

All (3109) | News (2412) | Reports (0) | Blogs (620) | Audio/Video (5) | Fact Sheets (32) | Press Releases (32)
sort by: Date | Relevance
Baxter gets C-suite lined up ahead of pharma sp... [Published FiercePharma - 3 mins ago]
Baxter BioScience Names R&D VP [Published Contract Pharma - 13 mins ago]
Novartis sees Alcon as $35M Fort Worth data center [Published Real Estate Center - 23 mins ago]
Novartis' Enbrel beater nears a soon-to-crowd p... [Published FierceBiotech - 26 mins ago]
Oral Octreotide Could Capture a Share of Inject... [Published PharmaAsia - 1 hour ago]
New psoriasis treatment from Novartis hits all ... [Published MedCity News - 1 hour ago]
Canadian Stocks Swept Up In Euro Zone Fears -- ... [Published RTTNews.com - 1 hour ago]
A Pre-Earnings Update On Gilead [Published Seeking Alpha - 1 hour ago]
Mold Infections of the Central Nervous System [Published New England Journal of Medicine - 1 hour ago]
Secukinumab in Plaque Psoriasis — Results of Tw... [Published New England Journal of Medicine - 1 hour ago]
Novartis' Phase III Results on Secukinumab Publ... [Published Zacks.com - 1 hour ago]
Novartis AG To Build $35 Million Data Center At... [Published BioSpace - 2 hours ago]
New Lions Health awards reward creativity [Published pharmaphorum - 2 hours ago]
Pulmonary Drug Delivery Systems Market A Brief ... [Published MyNewsDesk - 3 hours ago]
Microbix sues Novartis in Europe over Virusmax ... [Published Stockwatch - 3 hours ago]
Directionally good, but no big healthcare idea,... [Published Hindu Business Line - 3 hours ago]
Novartis gets positive result in psoriasis PhII... [Published Bio Spectrum Asia - 3 hours ago]
Insurers balk at pricey generic version of anci... [Published FiercePharma - 3 hours ago]
Abzena Announces Intention To Float [Published Noodls - 3 hours ago]
Two pivotal psoriasis studies demonstrate secuk... [Published Medical News Today - 3 hours ago]
Microbix Sues Novartis for Infringement of its ... [Published TVNewsCheck - 3 hours ago]
Pulmonary Drug Delivery Systems Market A Brief... [Published Scoop Asia - 3 hours ago]
VC-backed Veeva Systems adds to board of direct... [Published PE Hub Blog - 3 hours ago]
Canadian Stocks Set To Follow Global Equities L... [Published RTTNews.com - 3 hours ago]
Baxter Appoints John Orloff, M.D., Vice Preside... [Published Wall Street Select - 4 hours ago]
Microbix Sues Novartis For Virusmax Patent Infr... [Published RTTNews.com - 4 hours ago]
UK M&A activity stands by £37.5bn in H1 2014 [Published Business Money - 4 hours ago]
Novartis reports positive trial data for psoria... [Published Zenopa - 4 hours ago]
Pharma's Poor Reputation Doesn't Help In The Fi... [Published Forbes.com - 4 hours ago]
Microbix Biosystems Sues Novartis For Infringem... [Published RTTNews.com - 4 hours ago]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
VC-backed Veeva Systems adds to board of direct... [Published PE Hub Blog - 3 hours ago]
Veeva Systems , which is backed by Emergence Capital Partners, has appointed Paul Sekhri to its board of directors while founding directors Young Sohn and Kevin Spain have stepped down. Sekhri is senior vice president of integrated care at Sanofi. ...
Novartis AG (NVS) Showing Bullish Technicals [Published MarketIntelligenceCenter.com - 5 hours ago]
MarketIntelligenceCenter.com’s patented algorithms have chosen the Oct. '14 $90.00 call for a couple of hedged-trading ideas on Novartis AG (NVS). A traditional covered call on Novartis AG yields 2.42% (8.85% annualized, for comparison purposes only) ...
Novartis announces NEJM publication of two pivo... [Published PR Newswire: Health - 19 hours ago]
EAST HANOVER, N.J., July 9, 2014 /PRNewswire/ -- Novartis today announced that The New England Journal of Medicine (NEJM) published the results from two pivotal Phase III studies evaluating the interleukin-17A (IL-17A) inhibitor secukinumab (AIN457). ...
Potential Novartis AG (NVS) Trade Has 5.36% Dow... [Published MarketIntelligenceCenter.com - Jul 09 2014]
Novartis AG (NVS) traded between $89.39 and $90.43 before closing at $89.52 Tuesday and presents some attractive trading opportunities today. MarketIntelligenceCenter.com’s algorithms have picked a Jan. '15 $87.50 covered call for a net debit of about ...
ReportAlert.info - Novartis (VTC:NOVZn) Publish... [Published theCSRfeed - Jul 09 2014]
The report enhances the company's transparency in several key areas, including in human resources, supply chain and ethics, and aims to meet the needs and expectations of CR professionals by offering easy access to key data SOURCE: CorporateRegister.com ...
1 2 3 4 5 6 7 8 9 10 ...

Audio/Video

sort by: Date | Relevance
Big pharma braces for M&A wave [Published Reuters Video: Business - Apr 22 2014]
Novartis And GlaxoSmithKline Doing Deals [Published Wall Street Journal What's News - Apr 22 2014]
Novartis CEO: Revamp leaves us "fighting fit" [Published Reuters Video: Top News - Apr 22 2014]
Novartis CEO: Revamp leaves us "fighting fit" [Published Reuters Video: Business - Apr 22 2014]
Novartis reviews business but not rewards [Published Reuters Video: Business - Jan 29 2014]
1

Press Releases

sort by: Date | Relevance
New Board Director, Clinical Trial Results, New... [Published Financial Services - 8 hours ago]
Kosher Certifications, Biologic License Applica... [Published Financial Services - Jul 07 2014]
Early Briefing on Pharma Stocks -- Research on ... [Published Financial Services - Jul 02 2014]
Quark Announces Completion of Phase II Trial Ev... [Published GlobeNewswire: Advertising News - Jul 01 2014]
In Wake of General Motors (GM) and Department o... [Published GlobeNewswire: Acquisitions News - Jun 27 2014]
1 2 3 4 5 6 7
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.